CRIS Stock Summary and Trading Ideas (Curis | NASDAQ:CRIS)

Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Curis trades on the NASDAQ stock market under the symbol CRIS.

As of April 20, 2026, CRIS stock price climbed to $0.62 with 486,322 million shares trading.

CRIS has a beta of 2.89, meaning it tends to be more sensitive to market movements. CRIS has a correlation of 0.21 to the broad based SPY ETF.

CRIS has a market cap of $24.66 million. This is considered a Sub-Micro Cap stock.

Last quarter Curis reported $1 million in Revenue and -$.50 earnings per share. This fell short of revenue expectation by $-2 million and met earnings estimates .

In the last 3 years, CRIS traded as high as $19.60 and as low as $.49.

The top ETF exchange traded funds that CRIS belongs to (by Net Assets): VTI, VXF.

CRIS has underperformed the market in the last year with a return of -52.9%, while the SPY ETF gained +36.0%. In the last 3 month period, CRIS fell short of the market, returning -36.3%, while SPY returned +4.9%. However, in the most recent 2 weeks CRIS has outperformed the stock market by returning +15.7%, while SPY returned +7.6%.

CRIS support price is $.54 and resistance is $.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRIS shares will trade within this expected range on the day.